論文・技術情報追加のお知らせ

1. FAERS-Based Disproportionality Analysis of Diabetes Mellitus in Patients Treated with Biologics for Asthma and Related Conditions.

喘息治療用生物学的製剤の一部で糖尿病および代謝AEのリスク増加が確認

対象DB：FAERS

2. Evaluation of Safety of Elacestrant in Patients with Breast Cancer: Insights from Food and Drug Administration Adverse Event Reporting System Database Analysis.

エラセストラントの安全性をRWDで評価

対象DB：FAERS

3. Pharmacovigilance insights into drug-associated venous thromboembolism.

薬剤関連VTEリスク、135薬剤で確認。抗腫瘍薬・免疫調節薬に高リスク

対象DB：FAERS

4. What drives hyperammonemic encephalopathy in AED users: monotherapy risks or polypharmacy perils?

抗てんかん薬(VPA, PER等)とHEリスク。併用療法で危険増加

対象DB：FAERS

5. Exploring tumor lysis syndrome linked to immune checkpoint inhibitors: insights from the FAERS pharmacovigilance database.

免疫チェックポイント阻害剤とTLSの関連が判明

対象DB：FAERS

6. Real-world safety profile of etelcalcetide in dialysis-related secondary hyperparathyroidism: a pharmacovigilance analysis of FAERS data.

エテルカルセチドは低カルシウム血症や心血管リスクと関連

対象DB：FAERS

7. Gender differences in drug-induced precocious puberty: a real-world analysis of adverse event reports from the FDA FAERS database (2004-2024).

薬剤誘発性早発思春期は小児で注意が必要

対象DB：FAERS

8. A study on adverse events of botulinum toxin type A in real-world applications: A FAERS database analysis.

BoNT-A使用における予期せぬ副作用判明

対象DB：FAERS

9. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis associated with the use of immune checkpoint inhibitors: A disproportionality analysis using the FDA Adverse Event Reporting System database.

免疫チェックポイント阻害剤でSJS/TENリスク

対象DB：FAERS

10. Real-world data and Mendelian randomization analysis in assessing adverse reactions of rilonacept.

リロナセプト、皮膚・免疫・心疾患に副作用リスク。慎重な監視が重要

対象DB：FAERS

11. Cardiovascular toxicities associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a pharmacovigilance study based on FDA adverse event reporting system.

VEGFR-TKIの心血管毒性判明。高血圧やQT延長、心不全に注意が必要

対象DB：FAERS

12. Evaluating safety risks of ischaemic colitis with taxanes: a disproportionality analysis based on FDA adverse event Reporting system.

タキサン系薬剤と虚血性大腸炎の関連性を示唆

対象DB：FAERS

13. Evaluating Triptan Safety in Pediatric Migraine Management: A Comprehensive Pharmacovigilance Analysis.

トリプタン、小児患者の年齢別副作用リスク分析

対象DB：FAERS

14. Exploration of adverse event profiles for cefotaxime: a disproportionality analysis using the FDA adverse event reporting system.

セフォタキシム、副作用信号に地域・患者特性差

対象DB：FAERS

15. A real-world data analysis of montelukast in FDA Adverse Event Reporting System (FAERS) database.

モンテルカストの未記載副作用をFAERS分析で特定

対象DB：FAERS

16. Assessment of drug induced hyperuricemia and gout risk using the FDA adverse event reporting system.

薬剤誘発性高尿酸血症・痛風、FAERSデータで関係性特定

対象DB：FAERS

17. MDDC: An R and Python package for adverse event identification in pharmacovigilance data.

新R・Pythonパッケージ「MDDC」、薬剤安全性監視効率化

対象DB：EudraVigilance,FAERS,VigiBase

18. Pharmacovigilance study of drug-induced eye movement disorder based on FDA adverse event reports from 2004 to 2024.

薬剤性眼球運動障害、高リスク薬特定

対象DB：FAERS

19. Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database.

ICI併用療法、副作用多様で早期頻発。継続的監視重要

対象DB：FAERS

20. An investigation of drug-induced mental disorders in the children and adolescents population utilizing the FDA adverse event reporting system.

小児薬剤性精神障害、特定薬でリスク増。注意必要

対象DB：FAERS

21. A disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the FAERS database.

ビスホスホネート、心不整脈リスクあり。薬剤ごとに影響異なる

対象DB：FAERS

22. Disproportionality analysis and risk factor assessment of drug-associated thyroid dysfunction adverse events: a study based on the FAERS database.

薬剤誘発性甲状腺機能障害、抗腫瘍薬で多発

対象DB：FAERS

23. Hypoparathyroidism induced by immune checkpoint inhibitors: a review of literature reports and real-world pharmacovigilance data.

ICI誘発性副甲状腺機能低下症、早期診断にCa・PTH測定重要

対象DB：FAERS

24. Real-world safety of carboplatin in non-small cell lung cancer: a retrospective signal detection and subgroup analysis based on the FAERS database.

カルボプラチン、副作用リスク男女・高齢で変動

対象DB：FAERS

25. PD-1/PD-L1 inhibitor-induced hyponatremia: a real-world pharmacovigilance analysis using FAERS database.

PD-1/PD-L1阻害薬、低ナトリウム血症注意

対象DB：FAERS

26. A cautionary note regarding the use of the FDA adverse event reporting system.

FDA副作用報告は因果証明できず、解釈に慎重さ必要

対象DB：FAERS

27. Drug-Associated Alcohol Intolerance: A Real-World Disproportionality Analysis Study.

薬物誘発性アルコール不耐性、抗菌薬などで顕著

対象DB：FAERS

28. Association between finasteride with subjective memory deficits: a study from the NHANES and FAERS databases.

フィナステリド、記憶障害リスク示唆、認知監視要

対象DB：FAERS

29. Postmarketing safety surveillance of 177Lu-DOTA-TATE (LUTATHERA): an observational, pharmacovigilance study leveraging FAERS database.

ルタチラ、新規重篤事象を含む安全性データ強化

対象DB：FAERS

30. Abortion adverse events associated with adalimumab, etanercept, ustekinumab, and dupilumab during pregnancy: A pharmacovigilance study based on FDA adverse event reporting system.

アダリムマブ、エタネルセプト、ウステキヌマブ、妊娠関連流産リスク微増

対象DB：FAERS,JADER

31. Disproportionality Analysis of Ivabradine in the US FDA Adverse Event Reporting System: A Real-World Study Across Overall and Indication-Specific Populations.

イバブラジン、安全性良好も心疾患で事象異なる

対象DB：FAERS

32. Disruption of small intestinal mucosal homeostasis in mice with amiodarone induced steatohepatitis.

アミオダロン、腸内バリア機能障害を介しMASH発症促進

対象DB：JADER

33. Comparative assessment of endoscopic and microsurgery resection for intracranial ventricular tumors: a meta-analysis of 3059 patients.

内視鏡手術、脳室腫瘍管理で死亡率・合併症減少

対象DB：JADER

34. Factors associated with the completeness of information provided in adverse drug reaction reports of physicians, pharmacists and consumers from Germany.

ADR報告の完全性は患者年齢と因果関係で影響

対象DB：EudraVigilance

35. Pharmacovigilance on Dexamethasone 1 mg/mL + Levofloxacin 5 mg/mL Eye Drops, Solution: A Five-Year Registry.

レボフロキサシン/デキサメタゾンは安全性良好

対象DB：EudraVigilance

36. Glucocorticoid withdrawal syndrome: Disproportionality analysis of cases using VigiBase data.

ヒドロコルチゾンとベタメタゾンはGWSリスク最高

対象DB：VigiBase

37. Cardiotoxicity of combined pegylated liposomal doxorubicin and bevacizumab therapy: a propensity-matched cohort study and disproportionality analysis.

PLDとベバシズマブ併用で心毒性リスク増加注意

対象DB：VigiBase

38. Pazopanib and antacids: insights from the WHO pharmacovigilance database.

パゾパニブと制酸剤の併用で効果と毒性低下注意

対象DB：VigiBase

39. Enhancing Pharmacovigilance in Pharmaceutical Companies: A Comparative Study of Electronic Reporting Before and After Implementation.

電子報告は効果的だが採用促進が必要

対象DB：VigiBase

40. What Antiepileptics Have the Highest Risk of Parkinsonism? A Disproportionality Analysis in the World Health Organisation Pharmacovigilance Database.

バルプロ酸は抗てんかん薬中でDIPリスク最高

対象DB：VigiBase

41. Prolonged administration of ritodrine hydrochloride in women with premature labor or threatened premature delivery based on empirical data in Japan.

日本でリトドリン長期投与は減少傾向だが地域差あり

対象DB：DPC

42. Postoperative risks of type 2 diabetes in elderly hip fracture patients: a propensity score-matched study.

2型糖尿病は大腿骨骨折手術後の転帰悪化要因

対象DB：DPC

43. Clinical outcomes of flomoxef versus cefmetazole in hospitalized patients with urinary tract infections: combined retrospective analyses of two real-world databases and in vitro data.

UTI治療でフロモキセフはセフメタゾールと同等で安全

対象DB：JMDC

44. Trends in paediatric otitis media revealed in national health insurance data in Japan.

COVID-19で日本の小児中耳炎の発生率が減少

対象DB：NDB

45. Effectiveness of Corticosteroids on Persistent Inflammation, Immunosuppression, and Catabolism Syndrome in Patients with Septic Shock: A Retrospective Claims Database Study.

敗血症性ショック患者のPICS発生率にステロイドの影響なし

対象DB：MDV

46. Pain and Sedative Medication Use Among Individuals With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study.

IBD患者で鎮痛・鎮静薬の長期処方が多い

対象DB：CPRD